Navigation Links
Bionovo Presents Positive Results from Phase 1B Trial of Bezielle for Metastatic Breast Cancer
Date:8/4/2009

EMERYVILLE, Calif., August 4 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI) today announced positive results from the Phase 1B clinical trial of Bezielle (formerly BZL101), their lead drug candidate for advanced breast cancer. In the trial, Bezielle showed an excellent safety and tolerability profile, and also showed promising indications of efficacy in a difficult-to-treat population.

The Phase 1B clinical trial was conducted at eight US clinical sites under the directorship of Dr. Charles Shapiro, Professor of Medicine and Director of Breast Oncology at Ohio State University. The primary objective of the study was to identify the maximum tolerated dose of Bezielle and to determine the safety, feasibility and preliminary efficacy of the Company's novel, oral, anticancer therapy. A total of twenty-seven women with metastatic breast cancer were enrolled to the Phase 1B trial.

To date, 48 women with advanced breast cancer have been successfully treated with Bezielle in two early clinical trials. In a previous Phase 1A study, Bezielle demonstrated very limited toxicity with a favorable tolerability profile and encouraging clinical activity among a cohort of patients with metastatic breast cancer who had been heavily pretreated with anticancer therapies. Results from this second Phase 1B study provide further support that Bezielle is safe and well-tolerated, with early signs of clinical efficacy.

Safety Analysis

In comparison to other oral cytotoxic agents, Bezielle was extremely safe and well tolerated. No drug-related deaths or serious adverse events occurred during the study, and 94% of all drug-related adverse events were classified as grade 1 and 2 side effects per the National Cancer Institute Common Terminology Criteria for Adverse Events. The mo
'/>"/>

SOURCE Bionovo, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Bionovo Announces Closing of Public Offering of Common Stock
2. Bionovo Describes a New Class of Therapeutic Compounds
3. Bionovo Announces 2007 Financial Results and Highlights
4. Bionovo to Present at the Cambria Capital Investor Meeting
5. John D. Baxter, M.D. Joins Bionovos Board of Directors
6. Bionovo to Present at the Rodman & Renshaw 10th Annual Global Investment Conference
7. Bionovo to Present Recent Findings of BN108, its Anticancer Agent, at the 31st Annual San Antonio Breast Cancer Symposium
8. Willa A. Hsueh, M.D., Joins Bionovos Scientific Advisory Board
9. Bionovo Announces Cost Control Measures Taken
10. Bionovo Announces Presentation at the National Cancer Institute
11. Jan Ake Gustafsson, M.D., Ph.D., Joins Bionovos Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... May 06, 2015 Healthcare jobs ... mark after launching in mid-February. The company connects hospitals, ... have previous experience in the industry. Likewise, job seekers ... According to Kyle Johnson, CTO, unique traffic to the ... first month: "Each new job posting brings targeted, interested ...
(Date:5/6/2015)... 06, 2015 The 2015 STEMtech conference ... Corporate Partner booth selection . Don’t miss this ... community college and university decision-makers from around the country. ... 2015, at the Arizona Grand in Phoenix. This beautiful ... on the doorstep of the South Mountain Preserve. The ...
(Date:5/6/2015)... May 06, 2015 Topical BioMedics, Inc., announces ... May 12th, from 12pm – 1pm, streamed live and then ... and open to the public by clicking on the following ... attendees are invited “real time” during the webinar, and questions ... , The topic for the May webinar is ...
(Date:5/6/2015)... (PRWEB) May 06, 2015 Cloud security ... today announced a strategic partnership to help small-to-medium businesses ... The two industry-leading companies are teaming up to transition ... , “We’re thrilled to welcome SafeMonk users to ... that the people behind SafeMonk, the global powerhouse SafeNet ...
(Date:5/6/2015)... Arizona (PRWEB) May 06, 2015 ... IMMEDIATE RELEASE , Med Ag Ventures, Inc. (MAV), ... manufacturing capacity of its Arizona based Phoenician Engineering ... grinders last September. MAV recently achieved profitability from ... network expanded from 100 at the end of ...
Breaking Medicine News(10 mins):Health News:Job Seekers Turn to JobMedic to Find Healthcare Positions - JobMedic.com Reaches 1,000 User Milestone 2Health News:STEMtech Conference Exhibitors Gain Access to Community College and University Representatives From Across the U.S. 2Health News:Topical BioMedics Hosts May Pain Management Webinar “What You need to Know about Fibromyalgia” 2Health News:Topical BioMedics Hosts May Pain Management Webinar “What You need to Know about Fibromyalgia” 3Health News:Topical BioMedics Hosts May Pain Management Webinar “What You need to Know about Fibromyalgia” 4Health News:Topical BioMedics Hosts May Pain Management Webinar “What You need to Know about Fibromyalgia” 5Health News:Sookasa Grows Globally With SafeMonk Partnership 2Health News:Sookasa Grows Globally With SafeMonk Partnership 3Health News:Cannibus Industry Start-Up Reaches Profitability While Expanding Its Proprietary Ancillary Medical Marijuana Product IP Portfolio 2
... State University of New Jersey have come up with ... determining the quality of mate in humans.// , ... mates among many animal species. Impressive dancers attract more ... association with computer scientist at the University of Washington ...
... Four women who lost their children in the tsunami last ... that enabled them to conceive again.// , ,Despite having ... Tamil Nadu in southern India will now be able to ... surgery called recanalization. , ,"We cannot get back our ...
... how old they get, never lose their beauty - they merely ... ,Jacqueline Saburido was a very normal girl who was in ... incident that occurred on the 19th of September 1999 changed her ... than 60% of her body was burnt. She lost her ears, ...
... Marie Rogers has won the right to fight for receiving the ... an aggressive type of breast cancer and wants to make sure ... the disease is in its early stage has meant that the ... have already taken legal recourse for the same. Even Patricia Hewitt, ...
... by Dr Michael Fenech studied the damage of excess alcohol on ... excess intake of // alcoholic beverages resulted in increased risk of ... the study, six men aged 21-26 stuck to a diet low ... of either complete red wine, red wine with the alcohol removed ...
... to have been responsible for much of the DNA among ... The tendency of human beings to live in settlements and ... selection process. ,One way to look for ... to study mutations called single-nucleotide polymorphisms (SNPs) - single-letter differences ...
Cached Medicine News:Health News:Recanalization enables Tsunami mourners to parent again 2Health News:The Looming Controversy Surrounding Facial Transplant 2Health News:DNA Underwent Changes Due To Culture 2
(Date:5/6/2015)...  IGI Laboratories, Inc. (NYSE-MKT: IG), a New ... presenting today at the Deutsche Bank 40th Annual Health Care ... and 7 th at The InterContinental Hotel, ... , CEO and President and Jenniffer Collins , Chief ... 6, 2015, at 3:30 p.m. ET.   The presentation will ...
(Date:5/6/2015)... LOUIS , May 6, 2015   Sigma-Aldrich Corporation ... and high technology company, today announced a $50,000 product ... a large-scale initiative to replicate key findings from recent ... project is a collaboration between the online research marketplace ... Open Science and the open-access journal eLife. ...
(Date:5/6/2015)...   Symbiomix Therapeutics today announced multiple milestones, ... of a $41 million Series A financing and positive ... a single oral dose of SYM-1219 for the treatment ... U.S. Food and Drug Administration (FDA) at an End-of-Phase ... the Phase 2 trial as one of two pivotal ...
Breaking Medicine Technology:Sigma-Aldrich Donates $50K in Products to the Reproducibility Project to Foster Replicable Research and Accelerate Scientific Discoveries in Cancer Biology 2Sigma-Aldrich Donates $50K in Products to the Reproducibility Project to Foster Replicable Research and Accelerate Scientific Discoveries in Cancer Biology 3Symbiomix Therapeutics Announces Closing of $41M Financing and Positive Results from a Pivotal Phase 2 Trial of SYM-1219 for the Treatment of Bacterial Vaginosis 2Symbiomix Therapeutics Announces Closing of $41M Financing and Positive Results from a Pivotal Phase 2 Trial of SYM-1219 for the Treatment of Bacterial Vaginosis 3Symbiomix Therapeutics Announces Closing of $41M Financing and Positive Results from a Pivotal Phase 2 Trial of SYM-1219 for the Treatment of Bacterial Vaginosis 4Symbiomix Therapeutics Announces Closing of $41M Financing and Positive Results from a Pivotal Phase 2 Trial of SYM-1219 for the Treatment of Bacterial Vaginosis 5
... , March 22 Cambrex Corporation (NYSE: ... GmbH (“IEP”), a privately held company that is a ... located in Wiesbaden, Germany and offers cost ... to the pharmaceutical industry, with the ability to utilize ...
... Ga. , March 22 GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), a biotechnology company that is developing and testing innovative ... serve as its investor relations and public relations agency. , ... , ... ...
Cached Medicine Technology:Cambrex Acquires IEP GmbH 2Cambrex Acquires IEP GmbH 3GeoVax Labs Engages The Investor Relations Group 2GeoVax Labs Engages The Investor Relations Group 3GeoVax Labs Engages The Investor Relations Group 4
Solid 4 mm blades. Locking thumb. Dull finish. Holes in bar decrease weight of speculum....
Open 14 mm blades with 6 mm lifting wings. Dull finish....
Open 10 mm blades. Dull finish....
Open wire style 16 mm blade with a wing tip twist giving the surgeon better on-axis accessibility....
Medicine Products: